DSM and Roquette to open commercial scale bio-based succinic acid plant in 2012

Mon May 9, 2011 2:16am EDT

* Reuters is not responsible for the content in this press release.

Royal DSM, the global Life Sciences and Materials Sciences company, and the French starch and starch derivatives company Roquette Frères today announce that they will build a commercial scale plant for the production of bio-based succinic acid, the first non-fossil feedstock derived chemical building block that allows customers in the chemical industry to choose a bio-based alternative with a lower eco-footprint for a broad range of applications, from packaging to footwear.

 

With a capacity of about 10 kilotons per year, the plant will be Europe's largest bio-based succinic acid facility. It is expected to come on stream in H2 2012 and will be built on the premises of Roquette in Cassano Spinola (Italy). Financial details of the investment will not be disclosed.

 

Succinic acid is a chemical building block used in the manufacture of polymers, resins, food and pharmaceuticals among other products. Bio-based succinic acid, a renewable and versatile chemical building block, is an alternative to petroleum-derived chemical building blocks such as adipic acid and 1.4-butanediol. As a result of price competiveness and its renewable nature, bio-based succinic acid is addressing a larger market than fossil feedstock based succinic acid.

 

The commercial scale bio-based succinic acid plant is another important step in the successful cooperation between DSM and Roquette that started in 2008. Early 2010 DSM and Roquette opened a demonstration plant in Lestrem (France), which has been running at full capacity. In 2010 DSM and Roquette also announced their intention to establish a joint venture (which will be carrying out business under the name Reverdia) for their cooperation, subject to regulatory approval.

 

The initial feedback from the market is very encouraging and proves that DSM and Roquette's choice to invest in bio-renewable alternatives for fossil feedstocks by using biotechnological routes is starting to pay off. In case the market develops as DSM and Roquette expect an even larger facility will be considered in the future.

 

Rob van Leen, Chief Innovation Officer of DSM, commented: "The time is right to capitalize on the tremendous progress we have made together with Roquette in the last two years. Our proprietary yeast-based fermentation process not only allows cost effective production; it also eliminates salt waste and other by-products and thus improves the overall eco-footprint of end-products. This bio-based chemical building block is a substitute for various fossil feedstock derived monomers and proves that the bio-based economy is no longer a distant prospect."

 

To optimally combine its competences in Life Sciences and Materials Sciences, DSM has set up Emerging Business Areas, including DSM Bio-based Products & Services and DSM Biomedical, for which ambitious growth perspectives have been defined including an aspiration to achieve more than € 1 billion in sales in 2020.

 

Jean-Bernard Leleu, Deputy CEO and RID Director of Roquette, commented: "We are very encouraged with the development efforts in several new applications and are receiving favorable feedback from customers who have sampled ton quantities from our demonstration plant in Lestrem. The new plant in Italy will allow customers in Europe, North America and Asia to make larger volume commitments to their customers."

 

The new commercial production facility in Italy will be producing fermentation based bio-succinic acid. The proprietary yeast-based fermentation process, which operates at a much lower pH than competing processes, allows succinic acid to be produced with a significantly higher energy efficiency compared to the traditional method. It is also one of the first bio-based processes that sequesters carbon dioxide in the production process.

 

The new production facility will for the time being use starch derivatives as feedstock. In the longer term the aspiration is to switch to second generation feedstock (cellulosic biomass).

 

Roquette - Offering the best of nature(TM)

Roquette, one of the world's leaders in biorefinery, derives over 700 products from six million tons of maize, wheat, peas and potatoes, and adds outstanding value to over 550,000 hectares of agricultural output. Roquette has annual sales of more than EUR 2.3 billion and employs some 6,400 people worldwide. Roquette is a private family business dedicated to long-term development in the fields of nutrition and health and plant-based chemistry. Roquette serves customers all over the world in the human nutrition, animal nutrition, pharmaceuticals/cosmetics, paper/corrugated cardboard,  and chemicals/bioindustry sectors. The company is headquartered in Lestrem (France). Roquette Italia, located at Cassano Spinola (Alessandria province), is one of the Roquette Centres of expertise for fermentative products like gluconic acid. Roquette Italia has annual sales of more than EUR 350 Million and employs some 460 people. More information: www.roquette.com.

 

DSM - Bright Science. Brighter Living.(TM)

Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about € 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com

 

For more information:

DSM Corporate Communications

Herman Betten

tel. +31 (0) 45 5782017            

fax +31 (0) 45 5740680            

e-mail media.relations@dsm.com         
DSM Investor Relations

Hans Vossen

tel. +31 (0) 45 5782864

fax +31 (0) 10 4590275

e-mail investor.relations@dsm.com

 

Roquette Corporate Communications

Marie-laure Empinet

tel. +33 (3) 21 63 96 51            

e-mail marie-laure.empinet@roquette.com

 
Roquette RID Communication

Carole Petitjean

tel. +33 (3) 21 63 96 94

e-mail carole.petitjean@roquette.com



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: DSM N.V. via Thomson Reuters ONE

HUG#1513525
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.